 |
 |
|
"Alfacell Provides ONCONASE® NDA Submission Update"
Date: January 27, 2009
Client: Alfacell
Summary: Alfacell Corporation (OTCBB: ACEL) today reported that it has conducted a pre-NDA meeting with the U.S. Food and Drug Administration (FDA) to discuss the company's planned submission of the final components of the ONCONASE rolling New Drug Application (NDA) for the treatment of unresectable malignant mesothelioma (UMM) patients. At the pre-NDA meeting, the FDA provided guidance to the company recommending that an additional clinical trial be conducted in UMM patients that have failed one prior chemotherapy regimen, prior to submitting a NDA.
|
|
|
|
|
 |
|
"Clinical Update - Debio 025 in Hepatitis C"
Date: January 26, 2009
Client: Debiopharm Group
Summary: Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, announced today the randomisation of its first patient in a phase IIb clinical study with Debio 025, a selective cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C (HCV) effect. This multinational, double-blind, placebo-controlled, parallel-group study will investigate the efficacy and safety of three different treatment regimens combining Debio 025 with Peg interferon alpha 2a (peg-IFN?2a) and ribavirin in treatment-naïve chronic HCV genotype 1 patients.
|
|
|
|
|
 |
|
"Geron Receives FDA Clearance To Begin World's First Human Clinical Trial Of Embryonic Stem Cell-Based Therapy"
Date: January 23, 2009
Client: Geron
Summary: Geron Corporation (Nasdaq: GERN) announced today that the U.S. Food and Drug Administration (FDA) has granted clearance of the company's Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury.
|
|
|
|
 |
|
"F.D.A. Approves a Stem Cell Trial" - Andrew Pollack
Date: January 23, 2009
Client: Geron
Summary: In a research milestone, the federal government will allow the world's first test in people of a therapy derived from human embryonic stem cells. Federal drug regulators said that political considerations had no role in the decision. Nevertheless, the move coincided with the inauguration of President Obama, who has pledged to remove some of the financing restrictions placed on the field by President George W. Bush.
|
|
|
|
 |
|
"First Embryonic Stem-Cell Trial Gets Approval From the FDA" - Ron Winslow and Alicia Mundy
Date: January 23, 2009
Client: Geron
Summary: In a watershed moment for one of the most contentious areas of science and American politics, the U.S. Food and Drug Administration cleared the way for the first-ever human trial of a medical treatment derived from embryonic stem cells. Geron Corp., a Menlo Park, Calif., biotechnology company, is expected to announce Friday that it received a green light from the agency to mount a study of its stem-cell treatment for spinal cord injuries in up to 10 patients. The announcement caps more than a decade of advances in the company's labs and comes on the cusp of a widely expected shift in U.S. policy toward support of embryonic stem-cell research after years of official opposition.
|
|
|
|
 |
|
"US approves 1st stem cell study for spinal injury" - Malcolm Ritter
Date: January 23, 2009
Client: Geron
Summary: A U.S. biotech company says it plans to start this summer the world's first study of a treatment based on human embryonic stem cells - a long-awaited project aimed at spinal cord injury. The company gained federal permission this week to inject eight to 10 patients with cells derived from embryonic cells, said Dr. Thomas Okarma, president and CEO of Geron Corp. of Menlo Park, Calif.
|
|
|
|
 |
|
"Therapy that might have helped Christopher Reeve to walk again" - Mark Henderson
Date: January 23, 2009
Client: Geron
Summary: The first patients to receive a therapy based on embryonic stem cells are people who do not yet know that they will need it. The paralysis treatment that has been cleared to begin clinical trials is designed to work best in the first two weeks after a spinal cord injury - so those who may benefit are fit and healthy at the moment.
|
|
|
|
 |
|
"FDA Greenlights Testing of Geron's Stem Cell Treatment" - Mike Huckman
Date: January 23, 2009
Client: Geron
Summary: Just four days into the new administration a small biotechnology company is taking a giant step forward in the field of stem cell research. Geron is announcing that it has received U.S. Food and Drug Administration clearance to do the first-ever test of an embryonic stem cell treatment in people.
|
|
|
|
 |
|
"First Embryonic Stem-Cell Test Cleared for Geron Human Study" - Rob Waters
Date: January 23, 2009
Client: Geron
Summary: Geron Corp. won approval from U.S. regulators to begin the first human test of embryonic stem cells, treating people who have spinal cord injuries. The test will attempt to restore movement to paralyzed people by injecting neurons made from embryonic cells to the site of injury. The U.S. Food and Drug Administration today lifted a hold placed on the research last May after Geron convinced regulators the procedure is likely to be safe, said Thomas Okarma, chief executive officer of the Menlo Park, California-based company.
|
|
|
|
 |
|
"US allows use of embryonic stem cells" - Andrew Jack
Date: January 23, 2009
Client: Geron
Summary: US regulators have approved the first use of embryonic stem cells in humans. The move raises the prospect of a groundbreaking approach to medical treatment that had been blocked since 2001 by George W. Bush as president. Just two days after the inauguration of President Barack Obama, who opposed his predecessor's ban on federal funding for embryonic stem-cell research, the Food & Drug Administration authorised Geron, a US biotech company, to begin clinical trials for patients with severe spinal cord injuries.
|
|
|
|
 |
|
"Paralysed patients to be given pioneering stem cell treatment" - Mark Prigg
Date: January 23, 2009
Client: Geron
Summary: The controversial experiments are to begin within months in what experts hail as a new era for medicine. Stem cells have the ability to grow into any cell in the body. It is hoped that by injecting them into patients, the cells will prompt regrowth of damaged nerves, restoring sensation and movement.
|
|
|
|
 |
|
"US to carry out first human stem cell trials"
Date: January 23, 2009
Client: Geron
Summary: US biotech firm Geron Corp. announced on Friday it had been cleared to carry out the first human trials using embryonic stem cells, testing the therapy on patients paralysed by spinal-cord injury. The Menlo Park, California firm said in a statement that the US Food and Drug Administration (FDA) had cleared it for the first phase of trials of a novel therapy called GRNOPC1.
|
|
|
|
 |
|
"US Approves First Trial Of Embryonic Stem Cells"
Date: January 23, 2009
Client: Geron
Summary: The US regulators have given the go ahead for a biotech company to carry out the world's first trial of a treatment using embryonic stem cells, in this case to treat victims of spinal cord injury that leaves them unable to walk.
|
|
|
|
 |
|
"Tragara Pays $112M to Jointly Develop S*BIO Compound" - Catherine Hollingsworth
Date: January 22, 2009
Client: S*BIO
Summary: Singapore-based S*BIO Pte. Ltd. has joined with San Diego-based Tragara Pharmaceuticals Inc. to develop a potential treatment for blood cancer and possibly solid tumors, in a deal worth up to $112.5 million.
|
|
|
|
 |
|
"Disrupting atherosclerosis" - Tim Fulmer
Date: January 22, 2009
Client: Carolus Therapeutics
Summary: A team of German and U.S. researchers has designed a peptide that decreases atherosclerotic lesions in mice by disrupting interactions between two platelet-derived chemokines. The findings have led to the formation of Carolus Therapeutics Inc., which is developing the peptide for cardiovascular and inflammatory disorders.
|
|
|
|
|
|
|
"S*BIO and Tragara Announce an Exclusive Worldwide License Agreement for Novel Multi-kinase Inhibitor SB1317"
Date: January 21, 2009
Client: S*BIO
Summary: S*BIO Pte Ltd and Tragara Pharmaceuticals Inc. today announced that S*BIO has granted a worldwide exclusive license to Tragara to develop and commercialize its novel multi-kinase inhibitor SB1317.
|
|
|
|
|
|
"Carolus Therapeutics Wants to be King of Cytokine Targeting" - Anette Breindl
Date: January 20, 2009
Client: Carolus Therapeutics
Summary: Their company may be young and, for the time being, mainly virtual, but the folks at Carolus Therapeutics do not shy away from thinking big. It’s named after Carolus Magnus, or Charlemagne, who in the first century A.D. founded an empire that eventually encompassed much of Europe.
|
|
|
|
|
|
"PCI: Spezialkatheter spart Stents und verbessert Ergebnisse"
Date: January 19, 2009
Client: Radi Medical Systems
Summary: Die Bestimmung der fraktionellen Flussreserve (FFR) ersparte in einer randomisierten Studie im New England Journal of Medicine (NEJM 2009; 360: 213-224) vielen Herzpatienten eine Stentimplantation und verbesserte gleichzeitig ihre Prognose. Ein Editorialist bleibt dennoch skeptisch, ob der von niederländischen Kardiologen entwickelte Spezialkatheter die Übertherapie bei der perkutanen koronaren Intervention (PCI) verhindern kann.
|
|
|
|
|
|
"The Stent Debate"
Date: January 19, 2009
Client: Radi Medical Systems
Summary: New research suggests doctors may be implanting too many artery-opening stents. A new study says patient outcomes could improve if they used a method called fractional flow reserve (FFR) or measurements of blood flow in the vessels of the heart.
|
|
|
|
|
|
"New Tool Could Prevent Needless Stents And Save Money, Cardiologist Says"
Date: January 19, 2009
Client: Radi Medical Systems
Summary: Doctors may be implanting too many artery-opening stents and could improve patient outcomes - and ultimately save lives - if they did more in-depth measurements of blood flow in the vessels to the heart. That's the finding of a study, to be published Jan. 15 in the New England Journal of Medicine, that evaluated the benefits of a new diagnostic tool to measure blood flow and determine whether stenting was the best option.
|
|
|
|
 |
|
"Directing Coronary Intervention Using Fractional Flow Reserve" - Beat J. Meyer, MD
Date: January 19, 2009
Client: Radi Medical Systems
Summary: Applying the surgical precept of complete coronary revascularization to percutaneous coronary intervention has led to the common belief that optimal results of PCI in patients with multivessel disease require revascularization of all stenotic lesions. However, little evidence supports this belief. In fact, revascularization of only the culprit lesions (those causing ischemia) might well be the most effective strategy for most contemporary PCI procedures.
|
|
|
|
|
|
"Fewer clogged arteries may need stents"
Date: January 16, 2009
Client: Radi Medical Systems
Summary: A new study gives fresh evidence that many people with clogged heart arteries are being overtreated with stents, and that a simple blood-flow test might help prevent unnecessary care. Fewer deaths, heart attacks and repeat procedures occurred when doctors implanted fewer of these tiny artery props, using the blood-flow test to decide when they were truly needed, the study found.
|
|
|
|
|
|
"Diagnostic tool could reduce needless stent procedures"
Date: January 16, 2009
Client: Radi Medical Systems
Summary: Scientists have tested a new diagnostic tool designed to determine whether stenting really is the best option for individual patients. Artery-opening stents are commonly used in patients with coronary artery disease, with some cardiologists routinely implanting a stent in any artery that looks significantly narrowed on X-rays from a coronary angiogram.
|
|
|
|
|
|
"FAME Study: Routine FFR Use Reduces Risks After Stenting Patients with Multivessel Disease"
Date: January 16, 2009
Client: Radi Medical Systems
Summary: St. Jude Medical Inc. today said results from the landmark FAME (Fractional flow reserve (FFR) vs. Angiography in Multivessel Evaluation) study, which demonstrate a statistically significant 30 percent difference in major adverse cardiac events (MACE) such as death, myocardial infarction and repeat revascularization, was published in the New England Journal and Medicine.
|
|
|
|
|
|
"Stents sind oft überflüssig und manchmal sogar gefährlich" - Werner Bartens
Date: January 16, 2009
Client: Radi Medical Systems
Summary: Das Herz auf Stütze rettet vielen Patienten das Leben. Drohen Kranzgefäße dichtzumachen, weiten Ärzte mit einem Ballon die verengten Adern. Häufig werden anschließend Stents eingesetzt. Die Gefäßstützen sollen das Gefäß offen halten. Damit sich an dem Fremdkörper keine Gerinnsel bilden, sind sie oft mit Medikamenten beschichtet. Allein in den USA werden jährlich etwa 1,2 Millionen Stents eingesetzt, in Deutschland sind es mehr als 300 000 Eingriffe jährlich. Jetzt zeigt ein internationales Ärzteteam, dass viele der etwa 600 Euro teuren Gefäßstützen überflüssig sind und Patienten unnötig in Gefahr bringen (New England Journal of Medicine, Bd. 360, S. 213, 2009).
|
|
|
|
|
|
"Test Could Rule Out The Need For Stents"
Date: January 15, 2009
Client: Radi Medical Systems
Summary: When someone has a blocked artery, doctors often use stents to keep the blood vessel open. Healthwatch reporter Kellye Lynn reports a new study now indicates stents may not always be the best approach. Although stents are an effective tool in treating clogged arteries, they do carry the risk of blood clots which can lead to heart attack or stroke. Now this latest research shows a little used test could rule out the need for stents.
|
|
|
|
|
|
"Fractional flow reserve guidance 'improves stenting outcomes'"
Date: January 15, 2009
Client: Radi Medical Systems
Summary: Using fractional flow reserve (FFR) to guide stent placement in multivessel coronary artery disease (CAD) reduces adverse events at 1 year, a large clinical trial has shown. Traditionally, the decision to stent a lesion during percutaneous coronary intervention (PCI) depends on the degree of stenosis as seen on angiography. However, angiography often overestimates or underestimates a lesion's functional severity, and in patients with multivessel disease it can be difficult to determine which lesions are causing ischemia and thereby warrant stenting.
|
|
|
|
|
|
Date: January 15, 2009
Client: Radi Medical Systems
Summary: Eine Druckmessung in verengten Herzarterien hilft, diejenigen Engstellen zu finden, die mit einem sogenannten Stent aufgeweitet werden müssen. So werden unnötige Behandlungen vermieden.
|
|
|
|
 |
|
"New Device May Help Doctors Use Fewer Stents, Save Money" - Anna Boyd
Date: January 15, 2009
Client: Radi Medical Systems
Summary: New research suggests that using a medical device from Little Canada-based St. Jude Medical could reduce the number of heart stents a patient needs. The device measures the blood flow in partially blocked heart arteries. It uses a pressure-sensitive wire to guide the placement of tiny wire mesh tubes, or stents, used to keep arteries free of clots. This is quite different from the traditional angioplasty used in such cases.
|
|
|
|
 |
|
"Druckmessung in Herzarterien macht Stent-Implantation effektiver"
Date: January 15, 2009
Client: Radi Medical Systems
Summary: Eine Druckdrahtmessunng in verengten Herzkranzgefäßen hilft diejenigen Engstellen zu identifizieren, die mit einem Stent aufgeweitet werden müssen. Patienten und die Gemeinschaft profitieren von der gezielten Therapie, weil unnötige Behandlungen vermieden und so die Kosten gesenkt werden. Das ist das Ergebnis der FAME-Studie mit 1005 Patienten aus 20 Zentren in Europa und den USA.
|
|
|
|
 |
|
"EINGRIFF AM HERZEN; Gefäßstützen sind oft überflüssig" - Heike Le Ker
Date: January 15, 2009
Client: Radi Medical Systems
Summary: Das glänzende Erfolgsmodell bekommt Kratzer: Die Stents genannten Gitterröhrchen zur Behandlung von verengten Gefäßen bergen Risiken. Eine neue Untersuchung zeigt, dass ein einfacher Test genauer bestimmt, wem die Gefäßstützen helfen - und wem nicht.
|
|
|
|
 |
|
"Device helps guide doctors during stent placement, study finds"
Date: January 15, 2009
Client: Radi Medical Systems
Summary: Researchers at Radi Medical Systems, a unit of St. Jude Medical, have developed a device designed to help surgeons position artery-clearing stents. In tests involving more than 1,000 patients, only 13.2% of those whose doctors used the product required a follow-up operation, experienced a heart attack or died within a year after the procedure.
|
|
|
|
 |
|
"FAME published: Fractional flow reserve-guided PCI significantly reduces clinical events" - Michael O'Riordan
Date: January 15, 2009
Client: Radi Medical Systems
Summary: Eindhoven, the Netherlands - The Fractional Flow Reserve versus Angiography for Guiding PCI in Patients with Multivessel Coronary Artery Disease (FAME) trial, a study showing that the routine measurement of fractional flow reserve (FFR) during angioplasty significantly improves clinical outcomes when compared with traditional angiography-guided treatment, is now published in the January 15, 2009 issue of the New England Journal of Medicine [1].
|
|
|
|
 |
|
"NEJM: FFR test could prevent needless stents and save money"
Date: January 15, 2009
Client: Radi Medical Systems
Summary: Doctors could improve patient outcomes if they did more in-depth measurements of blood flow in the vessels to the heart with fractional flow reserve (FFR) to determine if stenting was the best option, according to the FAME study published Jan. 15 in the New England Journal of Medicine.
|
|
|
|
 |
|
"St. Jude Blood Meter can reduce the risk of needless stenting: Study" - Nisha Bhatia
Date: January 15, 2009
Client: Radi Medical Systems
Summary: A new study indicates that the blood-flow meter developed by a $2.9 billion global medical device company, St. Jude Medical Inc., works effectively for patients with clogged arteries, by lowering the need for stenting and enhancing survival rates. St. Jude Medical Inc. is a company that works on a global level to increase awareness of people and provide them an easy access to the medical technologies that can make their lives better.
|
|
|
|
 |
|
"Blood-flow test helps reduce stents in narrowed heart arteries" - William Atkins
Date: January 15, 2009
Client: Radi Medical Systems
Summary: A German-U.K.-U.S.-Denmark study has learned that many narrowed or blocked arteries to the heart may not need stents if a blood-flow test is first performed. Such testing before surgery was found to reduce the risk of complications and death afterwards. The results of the study were published in the Thursday, January 15, 2009 issue of The New England Journal of Medicine. The article (volume 360:213-224, number 3) is entitled "Fractional Flow Reserve versus Angiography for Guiding Percutaneous Coronary Internention."
|
|
|
|
 |
|
"Study: Fewer clogged arteries need stents"
Date: January 15, 2009
Client: Radi Medical Systems
Summary: A new study suggests that many people with clogged heart arteries are being overtreated with stents and that a simple blood-flow test helps prevent unnecessary care.
|
|
|
|
 |
|
"Better Outcomes for Stents When Fractional Flow Reserve (FFR) is Used; Measuring Intracoronary Pressures Reduces Major Cardiac Events by 28% in FAME Study, Published in the New England Journal of Medicine" - Burt Cohen
Date: January 15, 2009
Client: Radi Medical Systems
Summary: Published in today's New England Journal of Medicine, are the results of the FAME study (Fractional Flow Reserve vs. Angiography for Multivessel Evaluation). The study concludes that: "Routine measurement of FFR in patients with multivessel coronary artery disease who are undergoing PCI with drug-eluting stents significantly reduces the rate of the composite end point of death, nonfatal myocardial infarction, and repeat revascularization at 1 year."
|
|
|
|
|
|
|
"FAME Study Published in New England Journal of Medicine"
Date: January 14, 2009
Client: Radi Medical Systems
Summary: St. Jude Medical, Inc. (NYSE:STJ) today announced the publication of results from the landmark FAME (Fractional flow reserve (FFR) vs. Angiography in Multivessel Evaluation) study that demonstrate a statistically significant 30 percent difference in Major Adverse Cardiac Events (MACE) such as death, myocardial infarction and repeat revascularization. The randomized, prospective, multi-center trial looked at 1,005 patients with multivessel coronary artery disease 12 months after receiving a stent and compared outcomes for patients whose treatment was guided by FFR to those whose treatment was guided only by angiography.
|
|
|
|
 |
|
"FAME Published: FFR Guidance Improves Outcomes in Multivessel Disease" -Kim Dalton
Date: January 14, 2009
Client: Radi Medical Systems
Summary: In patients with multivessel coronary disease who are angiographic candidates for percutaneous coronary intervention (PCI), measuring fractional flow reserve (FFR) in each artery and restricting stenting to ischemia-producing lesions results in a lower risk of major adverse events at 1 year, according to a study published in the January 15, 2009, issue of The New England Journal of Medicine. It also significantly reduces the number of stents implanted, contrast exposure, and overall cost.
|
|
|
|
 |
|
"St. Jude device may trim stent use; Study: Heart attack, death risks reduced" - Christopher Snowbeck
Date: January 14, 2009
Client: Radi Medical Systems
Summary: Using a medical device from Little Canada-based St. Jude Medical could reduce the number of heart stents used per patient, a new study suggests. But it's unclear whether the technology would, in turn, lead to an overall reduction in usage of heart stents - metal mesh tubes that are implanted to prop open diseased heart arteries after artery-clearing angioplasty is performed.
|
|
|
|
 |
|
"Fewer arteries may need stents"
Date: January 14, 2009
Client: Radi Medical Systems
Summary: A new study gives fresh evidence that many people with clogged heart arteries are being overtreated with stents and that a simple blood-flow test might help prevent unnecessary care.
|
|
|
|
 |
|
"Fewer Stents and Better Outcomes Are Hallmarks of Fractional Flow Reserve-Guided PCI" - Peggy Peck, reviewed by Zalman S. Agus, MD
Date: January 14, 2009
Client: Radi Medical Systems
Summary: Measuring fractional flow reserve during percutaneous coronary interventions improved outcomes and reduced the number of drug-eluting stents implanted compared with PCI guided by angiography alone, researchers found.
|
|
|
|
 |
|
"Wire helps doctors position stents better - report" - Gene Emery
Date: January 14, 2009
Client: Radi Medical Systems
Summary: A new device may help doctors decide the best way to use artery-clearing stents, reducing serious risks and unnecessary follow up procedures by 28 percent, U.S. researchers said on Wednesday. The device, made by a unit of medical device maker St. Jude Medical Inc, uses a pressure-sensitive wire to guide the placement of tiny wire mesh tubes, or stents, used to keep blood flowing through diseased heart arteries.
|
|
|
|
|
|
"Fewer clogged arteries need heart stents, study finds; blood-flow test can show which ones do" - Marilynn Marchione
Date: January 14, 2009
Client: Radi Medical Systems
Summary: A new study gives fresh evidence that many people with clogged heart arteries are being overtreated with stents, and that a simple blood-flow test might help prevent unnecessary care. Fewer deaths, heart attacks and repeat procedures occurred when doctors implanted fewer of these tiny artery props, using the blood-flow test to decide when they were truly needed, the study found. Results were published in Thursday's New England Journal of Medicine.
|
|
|
|
 |
|
"Blood Flow Measurement Boosts Stent Outcomes" - Ed Edelson
Date: January 14, 2009
Client: Radi Medical Systems
Summary: A sophisticated measure of blood flow to determine where artery-opening stents should be implanted is more effective than the X-ray examinations now commonly used, an international study finds. The technique, measuring what's known as "fractional flow reserve" (FFR), is designed for people who have multiple blockages that require artery-opening procedures such as angioplasty, followed by implantation of the flexible tubes called stents, explained study co-author Dr. Nico H. J. Pijls, professor of cardiology at the Catharina Hospital in Eindhoven, the Netherlands.
|
|
|
|
 |
|
"Blood Flow Measurement Boosts Stent Outcomes" - Ed Edelson
Date: January 14, 2009
Client: Radi Medical Systems
Summary: Jude Medical, Inc. (St. Paul, MN) announced the publication of results from the FAME (Fractional Flow Reserve [FFR] Versus Angiography for Multivessel Evaluation) study that demonstrated a statistically significant 30% difference in major adverse cardiac events (MACE), including death, myocardial infarction (MI), and repeat revascularization. FAME's coprincipal investigators Nico Pijls, MD, and William F. Fearon, MD, published the study in the New England Journal of Medicine (2009;360:213-224). The 12-month FAME data was initially presented in October 2008 at the Transcatheter Cardiovascular Therapeutics meeting in Washington, DC.
|
|
|
|
|
|
"St. Jude Blood-Flow Meter Cuts Heart Stent Need, Extends Lives" - Alex Nussbaum
Date: January 14, 2009
Client: Radi Medical Systems
Summary: JSt. Jude Medical Inc.'s blood-flow meter cut the need for stents in patients with clogged arteries by a third and boosted their survival rate, a study found. The probe, which measures the severity of blockages, also cut the cost of care by an average of $675 a patient, according to the study, published online today in the New England Journal of Medicine. Heart attacks and deaths were trimmed 35 percent, the research found. The research should increase use of the device, called a fractional-flow reserve meter, William Fearon, an author of the study, said in a telephone interview. St. Jude acquired the decade-old technology in a $250 million deal Dec. 21. The findings may prompt some doctors to limit use of stents, the mesh tubes sold by Boston Scientific Corp.,Abbott Laboratories and Medtronic Inc. in a $4 billion-a-year market.
|
|
|
|
 |
|
"febit Appoints Heinz Blunier as COO"
Date: January 13, 2009
Client: febit
Summary: febit holding GmbH, a developer of the flexible and automated biochip-based DNA-analysis platform Geniom®, today announced the appointment of Heinz Blunier to the newly created position of Chief Operation Officer.
|
|
|
|
 |
|
"ANA598 Demonstrates Potent Antiviral Activity In An Early Clinical Study In HCV-Infected Patients"
Date: January 8, 2009
Client: Anadys Pharmaceuticals
Summary: Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) today announced results from the first cohort of an ongoing Phase Ib clinical trial of ANA598, the Company's investigational non-nucleoside polymerase inhibitor. ANA598 was very well-tolerated and demonstrated potent antiviral activity in patients infected with chronic Hepatitis C virus (HCV) in this first cohort of the study.
|
|
|
|
 |
|
"S*BIO Announces a Collaboration with Onyx Pharmaceuticals worth up to US$550 Million"
Date: January 6, 2009
Client: S*BIO
|
|
|
|
|
|
Alfacell Announces Receipt of NASDAQ Panel Decision
Date: January 5, 2009
Client: Alfacell
|
|
|
|
 |
|
Clarus Ventures Names Two New Partners
Date: January 5, 2009
Client: Clarus Ventures
|
|
|
|
|
|
Clarus Ventures Hires Former Merck President Ed Scolnick and Broad Institute Scientist Finny Kuruvilla
Date: January 5, 2009
Client: Clarus Ventures
|
|
|
|
 |
|
"Catching lymph disorder in time; Device aids early detection, treatment of condition that occurs after cancer surgery" - Stephanie Innes
Date: January 2, 2009
Client: ImpediMed
Summary: A Tucson doctor is hoping to bring earlier detection and more awareness of a condition that patients can develop after cancer surgery, particularly if the lymph nodes are removed, biopsied or irradiated. If untreated, it leaves its sufferers with bulging, unsightly and painful swelling for the rest of their lives. Dr. Eric B. Whitacre, director of the Breast Center of Southern Arizona and an American Society of Breast Surgeons board member, has begun using a new device that helps detect lymphedema in patients before it's too late.
|
